BELLUS Health Inc (BLU):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10043)
◆英語タイトル:BELLUS Health Inc (BLU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10043
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:36
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second indication called sarcoidosis; AMO-01 related to Fragile X syndrome and ALZ-801 for the treatment of Alzheimer’s disease. BELLUS Health is headquartered in Laval, Quebec, Canada.

BELLUS Health Inc (BLU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BELLUS Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Asclepios Bioresearch To Invest In Bellus Health 10
Licensing Agreements 11
BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 11
Bellus Health Enters into Licensing Agreement with AMO Pharma 12
Bellus Health Enters Into Licensing Agreement With FB Health For Vivimind 13
Bellus Health Enters Into Licensing Agreement With Alzheon For BLU8499 And Its Analogs 14
Equity Offering 15
BELLUS Health Raises USD15.8 Million in Private Placement of Shares 15
Acquisition 17
Taro Pharma To Acquire Thallion Pharma for USD2 Million 17
Bellus Health Completes Acquisition Of Thallion Pharma For US$6.3 Million 18
Pharmascience Acquires 10.4% Stake In Bellus Health For US$17.4 Million 19
BELLUS Health Inc – Key Competitors 21
BELLUS Health Inc – Key Employees 22
BELLUS Health Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: BELLUS Health reports financial and operating results for the second quarter ended june 30, 2018 24
May 15, 2018: BELLUS Health Announces Financial Results for the First Quarter Ended March 31, 2018 26
Feb 21, 2018: BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017 28
Nov 08, 2017: BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017 30
Aug 09, 2017: BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017 31
Feb 28, 2017: Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016 33
Corporate Communications 35
Sep 27, 2017: BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
BELLUS Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BELLUS Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BELLUS Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Asclepios Bioresearch To Invest In Bellus Health 10
BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 11
Bellus Health Enters into Licensing Agreement with AMO Pharma 12
Bellus Health Enters Into Licensing Agreement With FB Health For Vivimind 13
Bellus Health Enters Into Licensing Agreement With Alzheon For BLU8499 And Its Analogs 14
BELLUS Health Raises USD15.8 Million in Private Placement of Shares 15
Taro Pharma To Acquire Thallion Pharma for USD2 Million 17
Bellus Health Completes Acquisition Of Thallion Pharma For US$6.3 Million 18
Pharmascience Acquires 10.4% Stake In Bellus Health For US$17.4 Million 19
BELLUS Health Inc, Key Competitors 21
BELLUS Health Inc, Key Employees 22
BELLUS Health Inc, Subsidiaries 23

List of Figures
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ BELLUS Health Inc (BLU):製薬・医療:M&Aディール及び事業提携情報(BELLUS Health Inc (BLU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆